Articles By Matthew Pillar

31. From Racecars To Regenerative Medicine 12/14/2022

    Find out what inspired a mechanical engineer, a U.S. Marine veteran, and a racecar driver to launch a regenerative medicine company manufacturing perinatal tissue allografts and get its products to market at breakneck speed.

32. Data Confidence Drives Clinical, Financial Perseverance 12/7/2022

    Under the leadership of Mai-Britt Zocca, Ph.D., IO Biotech raised a $150 million Series B during a pandemic to move forward with a target that's seen its fair share of failure. To get there, the clinical stage biopharma leaned hard into its data differentiators.

33. Venture Philanthropy Launches Biotech From Within 11/23/2022

    There are more than 260 genes known to cause inherited retinal diseases, and Opus Genetics’ discovery and development work is leaving none of those stones unturned. The company’s genesis story is unique, though replicable and representative of a greater trend among emerging biopharmaceutical companies.

34. Computational Biology Speeds The Path To Clinical Studies 11/17/2022

    Computer-aided 3D modeling enables quick assessment of previously undiscovered protein binding sites and helps scientists at Gain Therapeutics marry them to the correct therapeutic molecules. Find out how the approach works, and its role in accelerating the company’s path to the clinic in Parkinson’s disease. 

35. From Sales To The C-Suite Of Pioneering Gene Therapy 11/15/2022

    AviadoBio is building a pipeline of investigational gene therapies for neurodegenerative diseases. Its lead preclinical candidate is AVB-101 for GRN frontotemporal dementia (FTD-GRN). It’s an intra-thalamic gene supplementation therapy, and as it heads to clinical trials, it's being overseen by a ladder climber who's seen it all.

36. Where Biotech Business Nuance Isn’t Lost 11/14/2022

    You read, you watch, you listen, you travel to conferences and events, and you learn from all of it, but none of those are the leading source of information for those who seek it. What medium do most biopharma leaders actively seek when it’s learning they’re yearning? Conversation.

37. Are Immunotherapeutic Vaccines The Next Biologic Revolution? 11/9/2022

    Vaxxinity, small as it may be on the greater pharma landscape, is carving out positions as innovator, disruptor, and leader in what CEO Mei Mei Hu, J.D. refers to as the third biologic revolution. Here, she shares Vaxxinity's position on immunotherapeutic vaccines in the context of traditional vaccines and biologics and offers insight into the company's unique culture. 

38. Master The CMC-To-C-Suite Transition 10/26/2022

    Sarah Howell, Ph.D. joined Arecor as COO back in 2011. She brought drug development experience—and commercial success—honed at big pharmas including GSK, UCB, and BTG. What she didn’t bring with her was experience in the C-suite. Hers had had been spent on another C-level: CMC. Here's what Dr. Howell, now CEO, learned about the transition.

39. Nurturing Next-Gen Biopharma Manufacturing Skills 10/25/2022

    Turning academic interest in biology into careers in biopharma: A look at NIIMBL's commitment to nurturing the skilled workforce the industry desperately needs now—and will need even more as it moves into the development and production of increasingly complex ATMPs and multi-modal therapeutics.

40. Turning “White Paper Ideas” Into Biomanufacturing Realities 10/19/2022

    NIIMBL Director Kelvin H. Lee, Ph.D. illustrated the power of consortia and public/private partnerships in advancing next-generation approaches to ATMP manufacturing, and demonstrated how the Institute isn’t just talking — it’s building.